Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44 EUR | +0.69% | +1.62% | +69.23% |
Apr. 30 | Transcript : AlzChem Group AG, Q1 2024 Earnings Call, Apr 30, 2024 | |
Apr. 30 | AlzChem Group AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- With a P/E ratio at 10.92 for the current year and 9.77 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.86 for the current period. Therefore, the company is undervalued.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+69.23% | 482M | C+ | ||
+0.59% | 74.39B | B | ||
-0.70% | 46.81B | A- | ||
+2.60% | 32.84B | C | ||
+10.10% | 18.39B | B | ||
+10.28% | 11.69B | A- | ||
-0.92% | 10.77B | - | ||
-19.15% | 10.61B | B | ||
+1.25% | 9.27B | A- | ||
-7.04% | 8.17B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACT Stock
- Ratings AlzChem Group AG